Theleme Partners LLP Buys 72,028 Shares of Moderna, Inc. (NASDAQ:MRNA)

Theleme Partners LLP boosted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 1.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,306,861 shares of the company's stock after acquiring an additional 72,028 shares during the period. Moderna comprises approximately 20.4% of Theleme Partners LLP's holdings, making the stock its biggest holding. Theleme Partners LLP owned 1.90% of Moderna worth $303,819,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB grew its stake in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after acquiring an additional 587 shares during the period. Compass Planning Associates Inc purchased a new stake in Moderna in the 4th quarter worth approximately $37,000. Venturi Wealth Management LLC grew its stake in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares during the period. Crowley Wealth Management Inc. purchased a new stake in shares of Moderna during the 4th quarter valued at $41,000. Finally, Itau Unibanco Holding S.A. grew its stake in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after buying an additional 343 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Trading Down 7.8%

MRNA stock traded down $2.19 during trading on Wednesday, reaching $25.80. The stock had a trading volume of 17,764,362 shares, compared to its average volume of 8,001,828. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47. The company has a market capitalization of $9.98 billion, a P/E ratio of -2.78 and a beta of 1.99. The firm has a fifty day moving average price of $27.39 and a 200 day moving average price of $34.99.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same quarter in the previous year, the business posted ($3.07) EPS. The firm's revenue was down 35.3% compared to the same quarter last year. Sell-side analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. William Blair reissued a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Friday, March 21st. UBS Group lowered their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, Citigroup assumed coverage on shares of Moderna in a research note on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective for the company. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $53.95.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.